The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD

133/21-02-2022

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

2022-03-01

2023-03-01

2024-05-01

Recruiting

50

Inclusion Criteria: * Diabetes Mellitus type 2 * NAFLD Exclusion Criteria: * malignancies * chronic inflammatory disease * chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days) * peripheral vascular disease * retinopathy * previous therapy with a Glucagon-like peptide-1 agonist. * None of the female patients was on hormone replacement treatment.

{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '12 Months', 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Blood sample obtained from the subjects for oxidative stress markers (malondialdehyde and protein carbonyls), nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP) measuring.'}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}

2024-03-08